Bromocriptine induces regression of left ventricular hypertrophy in peritoneal dialysis patients

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Left ventricular hypertrophy (LVH) is highly prevalent in end-stage renal disease (ESRD) and predicts cardiac death in peritoneal dialysis patients.
• Norepinephrine, Angiotensin II, and aldosterone are implicated in cardiac hypertrophy.
• Dopamine, via DA2 receptors, inhibits norepinephrine release, antagonizes aldosterone, and down-regulates AT1 receptors, suggesting potential therapeutic roles for DA2 agonists.

Purpose of the Study:

• To evaluate the effect of bromocriptine (BEC), a DA2 agonist, on left ventricular mass in ESRD patients undergoing continuous ambulatory peritoneal dialysis (CAPD).

Main Methods:

• An open clinical trial involving 20 ESRD patients on CAPD.
• Fifteen patients received bromocriptine (BEC) 2.5 mg three times daily for three months; five served as a control group.
• M-mode echocardiography and plasma prolactin levels were measured pre- and post-treatment.

Main Results:

• The experimental group showed a 24.4% decrease in left ventricular mass index (LVMI) and an 11.3% decrease in interventricular septum thickness.
• No significant changes were observed in the ejection fraction.
• The control group exhibited no significant changes.

Conclusions:

• BEC-mediated reduction in left ventricular mass suggests that dopaminergic agonists may be beneficial for managing LVH in dialysis patients with ESRD.
• Further research into dopaminergic agonists for treating cardiovascular complications in ESRD is warranted.